Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

ARQ-234

Other · developed by Arcutis Biotherapeutics

Phase 1 Most advanced trial

ARQT Developer

1 Registered trials

What is ARQ-234?

ARQ-234 is an investigational subcutaneous injectable solution. It is studied in atopic dermatitis (eczema).

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Other
Therapy area: Dermatology
Developer: Arcutis Biotherapeutics, Inc. (ARQT)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07453602	Phase 1	Atopic Dermatitis (AD)	Recruiting	ARQT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Atopic Dermatitis (AD)Eczema

More from Arcutis Biotherapeutics

ARQ-154 Phase 2 ARQ-252 Phase 2

Sources

ClinicalTrials.gov NCT07453602

Updated Oct 11, 2026. Something wrong or missing? Report it on the ARQT page.

Follow ARQT, the company behind ARQ-234

See ARQT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ARQT catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z